Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Triple carbapenemase-producing Klebsiella pneumoniae ST6668 resistant to novel β-lactam/β-lactamase inhibitor combinations and cefiderocol, Northern Italy, 2025.

Created on 22 Aug 2026

Authors

Vittoria Mattioni Marchetti, Nicole Giorgi, Francesca Piscopiello, Ilaria Petrizzi, Aurora Piazza, Mariasofia Caltagirone, Antonella Rezzani, Loretta Fiorina, Silvana Telecco, Antonella Navarra, Roberta Migliavacca

Published in

International journal of antimicrobial agents. Pages 107977. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

Klebsiella pneumoniae ST6668 has recently emerged in Northern Italy, but data on its resistance architecture remain limited. We identified a K. pneumoniae ST6668 (KNVO1) strain co-producing NDM-1, VIM-1 and OXA-48 carbapenemases, via multiple megaplasmids, from an elderly hospitalized patient who experienced clinical deterioration during a prolonged period of healthcare exposure. KNVO1 showed resistance to all tested β-lactams, including novel β-lactam/β-lactamase inhibitor combinations and cefiderocol, with susceptibility retained only to colistin. Whole-genome sequencing confirmed the ST6668. Plasmidome included two megaplasmids (pKPC-CAV1321 and IncFIB:IncHI) carrying blaVIM-1 and blaNDM-1, respectively, and an IncL plasmid harbouring blaOXA-48. SNPs-based phylogeny demonstrated genomic distance to other ST6668 strains circulating locally, suggesting an independent introduction event. Conclusion. The convergence of three major carbapenemase families within ST6668, highlights the capacity of this clone to accumulate complex resistance determinants via megaplasmids, posing a serious threat to infection control and antimicrobial stewardship in healthcare settings.

PMID:
42628851
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement